1. Home
  2. TG vs ABOS Comparison

TG vs ABOS Comparison

Compare TG & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tredegar Corporation

TG

Tredegar Corporation

N/A

Current Price

$7.13

Market Cap

249.4M

Sector

Industrials

ML Signal

N/A

Logo Acumen Pharmaceuticals Inc.

ABOS

Acumen Pharmaceuticals Inc.

HOLD

Current Price

$2.93

Market Cap

197.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TG
ABOS
Founded
1988
1996
Country
United States
United States
Employees
1700
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
249.4M
197.9M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
TG
ABOS
Price
$7.13
$2.93
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.00
AVG Volume (30 Days)
129.0K
358.2K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
151.06
N/A
EPS
0.34
N/A
Revenue
$800,821,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$22.74
N/A
Revenue Growth
8.29
N/A
52 Week Low
$6.25
$1.21
52 Week High
$10.53
$3.60

Technical Indicators

Market Signals
Indicator
TG
ABOS
Relative Strength Index (RSI) 37.00 49.79
Support Level $7.14 $2.76
Resistance Level $8.12 $3.02
Average True Range (ATR) 0.20 0.18
MACD -0.04 -0.03
Stochastic Oscillator 0.61 16.39

Price Performance

Historical Comparison
TG
ABOS

About TG Tredegar Corporation

Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.

About ABOS Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Share on Social Networks: